Acutaas Chemical Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹437 Cr +42.8% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
AC

Acutaas Chemical

Q4 FY26Pharmaceuticals & Biotechnology

Acutaas Chemical Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹433Cr
+40.6% YoY
+10.2% QoQ
Net profit
₹134Cr
+112.7% YoY
+26.4% QoQ
Margin
42%
+14 pp YoY
+4 pp QoQ
Price₹3,169
Market cap₹25.9K Cr
P/E67.2

The short version

The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17). Revenue growth guidance for FY '27 is 25% CAGR, in line with the company’s history of over a decade.

From Acutaas Chemical's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17).
  • Growth drivers for FY '27 and beyond include:
  • Electrolyte additive division (battery chemicals).
  • Pharma intermediate business, which is the biggest growth engine.
  • Semiconductor chemical business, starting with BFC and Indichem JV in 2-3 years (Page 15).
  • CDMO business has a long-term 10-year contract ensuring visibility and revenue stability; with multiple new products in validation/commercial phases (Page 14-15).
  • Electrolyte additive capacity expansion underway; capacity of 2,000 MT indicates significant revenue potential (Page 14).
  • Seasonality effect expected but new contracts like Fermion ramp-up may reduce Q1 dips (Page 17).

2 more points from Acutaas Chemical's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Acutaas Chemical said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY '26 capex was INR195 crores focused on Jhagadia site for battery chemical project and pilot plant at Sachin site, plus maintenance.
  • Spillover capex of around INR50 crores related to electrolyte additive and pilot plant expected in FY '27.
  • FY '27 planned capex around INR90 crores (INR50 crores spillover + INR40 crores maintenance), excluding new R&D center costs.
  • New versatile R&D center planned with ~10x capacity expansion, covering pharmaceuticals, battery chemicals, semiconductors, electronics, cosmetics, and more.
  • Continued investment in the South Korea joint venture Indichem with INR190 crores invested in FY '26; plant commissioning expected in second half of calendar 2026.

2 more points from Acutaas Chemical's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Acutaas Chemical said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • For the CDMO business, Acutaas Chemicals has a confirmed long-term supply contract in place for 10 years with their first customer, providing good visibility and backlog.
  • The electrolyte additive segment has customer contracts already signed, covering the full 2,000 metric ton capacity for at least the next 3 years.
  • There are four additional CDMO products beyond the Fermion contract, validated and awaiting regulatory approval, with each expected to have a revenue potential of INR 50-100 crores at peak levels.

2 more points from Acutaas Chemical's call on order book

Create a free account to keep reading this call

Acutaas Chemical — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Acutaas Chemical Q4 FY26 results — key figures

Acutaas Chemical Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue433308+40.6%393+10.2%
Operating profit (EBITDA)18485+116.5%151+21.9%
Operating margin42%28%+14 pp38%+4 pp
Profit before tax18483+121.7%145+26.9%
Net profit (PAT)13463+112.7%106+26.4%
EPS (₹)16.097.63+110.9%13.19+22%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹437 Cr, net profit ₹123 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Acutaas Chemical and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Acutaas Chemical Q4 FY26 results?

The company has consistently guided a 25% CAGR revenue growth and is open to revising upward if business potential exceeds this (Page 17). Revenue growth guidance for FY '27 is 25% CAGR, in line with the company’s history of over a decade.

What is Acutaas Chemical share price analysis?

Acutaas Chemical currently shows a neutral. The stock trades at a P/E of 67.2 with a market cap of ₹25,945 Cr. Investors should review the full earnings analysis for detailed insights.

Is Acutaas Chemical planning capital expenditure?

FY '26 capex was INR195 crores focused on Jhagadia site for battery chemical project and pilot plant at Sachin site, plus maintenance.

Keep Acutaas Chemical on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.